The latest advances of the Ocular Gene and Cell Therapy Network (R-TGCO) were presented at the annual conference of the network on Wednesday November 26. Impulsed by Genethon, the network’s objective is to accelerate the development of clinical trials for genetic eye diseases.
The conference provided an update on the progress of the projects undertaken by members of the network. Treatments for genetic eye diseases are now at the forefront of innovative therapies and notably gene therapy, with several clinical trials in progress or in preparation. The results may also benefit very common diseases of the retina such as age-related macular degeneration, which affects 20% of the population over 50 years of age.
An initiative of AFM-Telethon
R-TGCO includes three laboratories financed by AFM-Telethon, members of the Institute for Biotherapies of Rare Diseases : Généthon, Atlantic Gene Therapies and I-Stem. In addition there are three other important partners, the Institut de la vision in Paris, the University Hospital (CHU) in Nantes and Inserm (National Medical Research Institute) in Montpellier. New participants this year include the Institut Pasteur, the Institut des Neurosciences de Montpellier, the CHU de Toulouse, the Hôpital Necker, the Hôpitaux Universitaires de Strasbourg, the Hôpital Ophtalmique Jules-Gonin (Lausanne), the Centre de Recherche des Cordeliers, the Association Retina France and theAssociation Syndrome de Wolfram.
Rare genetic diseases of the eye will be featured in the 2014 Telethon, notably through the the testimony of Mouna, one of the ambassadors of the Telethon. Link to Mouna’s testimony (in french).